Oncology – Page 21 – Medical News Asia

Increased cancer awareness improves survival, according to a recent study by Cancer Research UK (CRUK) published in the British Journal of Cancer (BJC). The researchers matched cancer symptom awareness from a population-based survey in over 35,000 people across the UK with the cancer registry.

ASCO Guideline NeoAdjuvant Chemotherapy for Ovarian Cancer Updated

27 September 2016/0 Comments/in Breast Cancer, Gynaecological Cancer, Oncology/by Stijn van den Borne, MSc

In women with stage IIIC or IV ovarian cancer, primary cytoreductive surgery (PCS) may be preferred when there is a high chance to achieve cytoreduction to <1 cm with acceptable morbidity. This was concluded by an expert panel who published clinical guidelines in the Journal of Clinical Oncology (JCO) this week.

IMM101 plus Gemcitabine Hopeful in Metastatic Pancreatic Cancer

25 September 2016/2 Comments/in Gastrointestinal Cancer, Oncology, Immunotherapy/by Stijn van den Borne, MSc

A phase II proof-of-concept (POC) study investigating the safety and tolerability of immune modulator IMM-101 plus gemcitabine vs. single agent gemcitabine in advanced pancreatic ductal adenocarcinoma (PDAC) showed significant improved progression-free survival (PFS) and overall survival (OS) in metastatic patients receiving the combination treatment.

Palbociclib (Ibrance®): First in Class CDK4/6 Inhibitor

17 September 2016/3 Comments/in Breast Cancer, Oncology, Targeted Therapies/by Stijn van den Borne, MSc

At the American Association for Cancer Research, 2014 annual meeting (AACR) Richard Finn presented the results of the PALOMA-1 study with Ibrance® (palbociclib), an oral inhibitor of cyclin-dependent kinase 4/6 (CDK4/6). Based on the results of this Phase 2 study, palbociclib was recently approved by the United States Drug and Food Administration (U.S. FDA). What is the current level of evidence on palbociclib in approved indications?

Ki67 in Breast Cancer: an overview

6 September 2016/3 Comments/in Breast Cancer, Oncology, Surgery, Targeted Therapies, Pathology, Translational Research/by Stijn van den Borne, MSc

Recent studies have shown new possible applications for Ki67. Huh et al. showed that low Ki67 levels in healthy breast tissue correlated with a lesser lifetime chance of breast cancer. Another study by Arnedos and colleagues concluded that palbociclib was able to invoke a significant Ki67-level drop. After a decade of Ki67-controversies, these results put the marker back in the spotlight.

ASCO16 Ribociclib & Abemaciclib Data

5 June 2016/Enter your password to view comments./in Breast Cancer, Oncology, Targeted Therapies/by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.